Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942208 | 0.87 | HMGCR (0.63) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL7080094 | 0.78 | HMGCR (0.51) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL7083575 | 0.78 | HMGCR (0.63) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL7083231 | 0.77 | HMGCR (0.49) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL9358182 | 0.75 | MEN1 (0.40) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL7759881 | 0.70 | NR1I2 (0.54) | HMGCRNR1I2MEN1KMT2A | |
| SCHEMBL7760639 | 0.69 | NR1I2 (0.53) | HMGCRNR1I2MEN1KMT2ACYP3A4 | |
| SCHEMBL7137096 | 0.67 | HMGCR (0.83) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL678403 | 0.67 | HMGCR (1.00) | HMGCRNR1I2MEN1GAAKMT2A | |
| SCHEMBL7080881 | 0.66 | HMGCR (0.62) | HMGCRNR1I2MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |